Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer

NCT00140556 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer
Pharynx Cancer

Interventions

RADIATION: Chemoradiotherapy
DRUG: Cisplatin
DRUG: Bevacizumab
DRUG: Erlotinib

Sponsor

David M. Brizel, MD

Collaborators

[object Object]
[object Object]